Table Selenium supplements and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response analysis Cases/ Author, Year, name, Study size Case Exposure RR (95%CI) Adjustment WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors Country (years) Klein, 2011 SELECT, 168/ Self report Questionnaire Incidence selenium and vit COL40894 Randomised 34 887 verified by 1.21 (0.81-1.81) e supplement vs North America Control Trial, 54 646 medical record Ptrend:0.22 placebo Age: 50- years, and pathology M, report 149/ selenium healthy men 0.96 (0.63-1.46) supplement vs Ptrend:0.79 placebo Lippman, 2009 SELECT, 123/ Self FFQ Incidence, selenium from COL40767 Randomised 35 533 colorectal cancer 1.05 (0.66-1.67) supp vs placebo USA Control 5.46 years Age: 50- years, reports 20/ Mortality, selenium from M 1.00 (0.32-3.16) colorectal cancer suppl vs placebo selenium and vit 1.49 (0.52-4.28) e vs placebo Bostick, 1993 IWHS, 212/ Population Incidence, colon Age, calories COL00483 Prospective 35 216 FFQ cancer, Intake, height, USA Cohort, 167 447 low-fat meat Age: 55-69 Intake, parity, years, total vitamin e yes vs no 0.60 (0.27-1.32) W Intake, total vitamin e x age, vitamin a supplement Intake
Table Selenium supplements and colorectal cancer risk. Main characteristics of studies included in the CUP SLR dose-response Author, Year, WCRF Code, Country name, characteristics Cases/ Study size Follow-up (years) Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Klein, 2011 COL40894 North America SELECT, Randomised Control Trial, Age: 50- years, M, healthy men 168/ 34 887 54 646 Self report verified by medical record and pathology report Questionnaire Incidence selenium and vit e supplement vs placebo 1.21 (0.81-1.81) Ptrend:0.22 149/ selenium supplement vs placebo 0.96 (0.63-1.46) Ptrend:0.79 Lippman, 2009 COL40767 USA SELECT, Randomised Control Age: 50- years, M 123/ 35 533 5.46 years Self reports FFQ Incidence, colorectal cancer selenium from supp vs placebo 1.05 (0.66-1.67) 20/ Mortality, colorectal cancer selenium from suppl vs placebo 1.00 (0.32-3.16) selenium and vit e vs placebo 1.49 (0.52-4.28) Bostick, 1993 COL00483 USA IWHS, Prospective Cohort, Age: 55-69 years, W 212/ 35 216 167 447 Population FFQ Incidence, colon cancer, yes vs no 0.60 (0.27-1.32) Age, calories Intake, height, low-fat meat Intake, parity, total vitamin e Intake, total vitamin e x age, vitamin a supplement Intake analysis
CUP_colorectal_SLR_2016_RO.docx